상세 보기
Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea
- Choi, Jung Yoon;
- Hong, Che Ry;
- Hong, Kyung Taek;
- Kang, Hyoung Jin;
- Kim, Seongkoo;
- ... Yoo, Keon Hee;
- 외 18명
WEB OF SCIENCE
5SCOPUS
7초록
Purpose Effectiveness and safety of clofarabine (one of the treatment mainstays in pediatric patients with relapsed/refractory acute lymphoblastic leukemia [ALL]) was assessed in Korean pediatric patients with ALL to facilitate conditional coverage with evidence development. Materials and Methods In this multicenter, prospective, observational study, patients receiving clofarabine as mono/combination therapy were followed up every 4-6 weeks for 6 months or until hematopoietic stem cell transplantation (HSCT). Response rates, survival outcomes, and adverse events were assessed. Results Sixty patients (2-26 years old; 65% B-cell ALL, received prior >= 2 regimen, 68.3% refractory to previous regimen) were enrolled and treated with at least one dose of clofarabine; of whom 26 (43.3%) completed 6 months of follow-up after the last dose of clofarabine. Fifty-eight patients (96.7%) received clofarabine combination therapy. Overall remission rate (complete remission [CR] or CR without platelet recovery [CRp]) was 45.0% (27/60; 95% confidence interval [CI], 32.4 to 57.6) and the overall response rate (CR, CRp, or partial remission [PR]) was 46.7% (28/60; 95% CI, 34.0 to 59.3), with 11 (18.3%), 16 (26.7%), and one (1.7%) patients achieving CR, CRp, and PR, respectively. The median time to remission was 5.1 weeks (95% CI, 4.7 to 6.1). Median duration of remission was 16.6 weeks (range, 2.0 to 167.6 weeks). Sixteen patients (26.7%) proceeded to HSCT. There were 24 deaths; 14 due to treatment-emergent adverse events. Conclusion Remission with clofarabine was observed in approximately half of the study patients who had overall expected safety profile; however, there was no favorable long-term survival outcome in this study.
키워드
- 제목
- Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea
- 저자
- Choi, Jung Yoon; Hong, Che Ry; Hong, Kyung Taek; Kang, Hyoung Jin; Kim, Seongkoo; Lee, Jae Wook; Jang, Pil Sang; Chung, Nack-Gyun; Cho, Bin; Kim, Hyery; Koh, Kyung-Nam; Im, Ho Joon; Seo, Jong Jin; Hahn, Seung Min; Han, Jung Woo; Lyu, Chuhl Joo; Yang, Eu Jeen; Lim, Young Tak; Yoo, Keon Hee; Koo, Hong Hoe; Kook, Hoon; Jeon, In Sang; Cho, Hana; Shin, Hee Young
- 발행일
- 2021-10
- 유형
- Article
- 권
- 53
- 호
- 4
- 페이지
- 1184 ~ 1194
- 언어
- ENG
- 출판사
- 대한암학회
- 발행국가
- 대한민국
- 분량
- 11 페이지
- ISSN
- E 2005-9256
P 1598-2998